IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.721
EU - Europa 8.934
AS - Asia 8.553
SA - Sud America 2.737
AF - Africa 208
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 39.197
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.955
SG - Singapore 3.601
RU - Federazione Russa 2.869
BR - Brasile 2.249
IT - Italia 2.046
CN - Cina 2.038
GB - Regno Unito 1.286
VN - Vietnam 1.242
DE - Germania 738
CA - Canada 560
HK - Hong Kong 546
UA - Ucraina 437
IE - Irlanda 248
SE - Svezia 236
FR - Francia 219
AR - Argentina 195
FI - Finlandia 173
IN - India 173
MX - Messico 155
PL - Polonia 147
ID - Indonesia 135
TR - Turchia 132
BD - Bangladesh 131
DK - Danimarca 122
IL - Israele 114
NL - Olanda 108
ZA - Sudafrica 99
EC - Ecuador 93
ES - Italia 90
JP - Giappone 89
IQ - Iraq 76
AT - Austria 70
PK - Pakistan 61
CO - Colombia 56
AE - Emirati Arabi Uniti 42
LT - Lituania 39
PY - Paraguay 39
UZ - Uzbekistan 38
MA - Marocco 34
CL - Cile 26
PE - Perù 26
VE - Venezuela 22
EU - Europa 21
UY - Uruguay 19
KE - Kenya 17
AZ - Azerbaigian 14
BE - Belgio 14
TN - Tunisia 14
SA - Arabia Saudita 13
EG - Egitto 12
RO - Romania 12
CH - Svizzera 11
DZ - Algeria 10
JO - Giordania 10
BO - Bolivia 9
DO - Repubblica Dominicana 9
IR - Iran 9
KZ - Kazakistan 9
PH - Filippine 9
AU - Australia 8
HN - Honduras 8
MC - Monaco 8
NZ - Nuova Zelanda 8
AM - Armenia 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
AL - Albania 6
BY - Bielorussia 6
LB - Libano 6
NI - Nicaragua 6
OM - Oman 6
TH - Thailandia 6
JM - Giamaica 5
KW - Kuwait 5
NP - Nepal 5
TW - Taiwan 5
BB - Barbados 4
BG - Bulgaria 4
CI - Costa d'Avorio 4
GE - Georgia 4
HU - Ungheria 4
KR - Corea 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
GR - Grecia 3
GT - Guatemala 3
GY - Guiana 3
IS - Islanda 3
LU - Lussemburgo 3
MK - Macedonia 3
MY - Malesia 3
NG - Nigeria 3
PA - Panama 3
PS - Palestinian Territory 3
RS - Serbia 3
SM - San Marino 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
Totale 39.153
Salva come PNG Salva come JPEG
Città #
Dallas 4.487
Singapore 1.933
Chicago 1.209
Ashburn 1.033
Beijing 1.001
Los Angeles 911
Southend 540
Salt Lake City 526
Hong Kong 504
Chandler 443
Moscow 433
Fairfield 411
Ho Chi Minh City 399
Buffalo 363
Woodbridge 330
San Mateo 329
Houston 325
Tampa 298
Wilmington 278
New York 273
Seattle 267
Ann Arbor 243
Dublin 240
Cambridge 236
Falls Church 232
Elk Grove Village 230
São Paulo 229
The Dalles 229
Hefei 218
Hanoi 209
Boardman 202
Jacksonville 183
Ottawa 182
Milan 180
Dearborn 162
Beauharnois 155
Portsmouth 153
Munich 145
Pisa 144
Stevenage 141
Santa Clara 134
Rome 128
Warsaw 127
Sterling 117
Dong Ket 115
Lawrence 106
Lancaster 105
Brooklyn 104
Tel Aviv 103
Montreal 98
London 93
Florence 88
Poplar 86
Tokyo 79
Rio de Janeiro 78
Miami 77
Frankfurt am Main 75
Phoenix 75
Istanbul 72
Denver 71
Stockholm 71
Johannesburg 68
Dulles 65
Atlanta 64
Mexico City 62
Nuremberg 62
Chennai 60
Orem 58
Belo Horizonte 53
Turku 51
Helsinki 50
San Diego 47
Lappeenranta 46
Detroit 45
Kansas City 45
Toronto 45
Amsterdam 42
Manchester 42
Boston 41
Brasília 41
Querétaro 40
Fremont 39
Washington 39
Porto Alegre 38
Curitiba 36
Haiphong 36
Redwood City 36
San Francisco 36
Council Bluffs 35
Tashkent 35
Bologna 34
Da Nang 34
Pittsburgh 34
Guangzhou 33
Ankara 32
Quito 32
Biên Hòa 31
Guayaquil 31
Lucca 31
Genoa 30
Totale 23.687
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.791
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.591
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.505
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 657
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 656
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 547
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 328
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 322
A simple echocardiographic score to rule out cardiac amyloidosis 302
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 298
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 291
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 276
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 275
Adrenergic activation in heart failure: blockade or rebalance? 271
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 271
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 265
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 256
A simple echocardiographic score to rule out cardiac amyloidosis 254
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 243
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 243
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 240
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 237
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 237
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 233
How to take arms against central apneas in heart failure 232
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 231
Sex-related differences in chronic heart failure 231
Cardiac light-chain deposition disease relapsing in the transplanted heart 229
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 228
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 225
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 223
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 221
Update sui biomarcatori nello scompenso cardiaco. 220
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 218
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 217
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 217
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 217
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 216
Screening the health status of people working in a university 215
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 215
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 214
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 214
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 211
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 210
[Ten perspectives for research and innovation in cardiac amyloidosis] 207
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 205
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 204
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 203
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 202
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 202
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 201
Atrial amyloidosis: mechanisms and clinical manifestations 199
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 199
Biomarkers for the diagnosis and management of heart failure 198
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 198
Prognostic value of plasma Renin activity in heart failure. 197
The search for efficient diagnostic and prognostic biomarkers of heart failure 194
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 190
Biomarkers for the diagnosis and management of heart failure: New frontiers 188
Modern diagnostic and therapeutical approach to cardiac AL amyloidosis and neuroendocrine model of heart failure: lessons from a clinical case. 187
Eligibility for vericiguat in a real‐world, contemporary heart failure population 186
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 184
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 184
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 182
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 181
Upright Cheyne-Stokes Respiration in Patients With Heart Failure 179
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 178
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome 178
Role of Imaging in Cardiomyopathies 175
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 175
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 175
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 175
Management of complications of cardiac amyloidosis: 10 questions and answers 174
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 173
Renin profiling predicts neurohormonal response to sacubitril/valsartan 173
Cardiogenic shock and acute kidney injury: the rule rather than the exception 171
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 171
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 171
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 170
Subclinical cardiac damage in cancer patients before chemotherapy 167
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 166
Valvular heart disease in patients with cardiac amyloidosis 166
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 166
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 166
Molecular autopsy of sudden cardiac death in the genomics era 166
Classification of patients with cardiac amyloidosis using machine learning models on Italian electronic clinical health records 165
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 164
Disease features and management of cardiomyopathies in women 164
Heart, kidney and FGF23: Les liaisons dangereuses 164
Epidemiological and clinical boundaries of heart failure with preserved ejection fraction 163
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 163
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 162
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 161
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 161
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 161
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 160
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 160
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 159
RNA-targeting and gene editing therapies for transthyretin amyloidosis 158
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure 157
Totale 25.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 202.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 202.190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.512 0 0 0 0 0 286 198 136 187 151 243 311
2021/20221.911 161 295 80 196 74 67 201 333 141 195 36 132
2022/20231.334 109 110 62 140 164 175 36 120 251 30 82 55
2023/20241.331 76 36 239 101 73 120 102 65 51 75 55 338
2024/202513.502 112 132 487 200 420 489 1.183 2.120 812 2.024 3.134 2.389
2025/202616.651 1.474 4.063 3.958 3.848 2.785 523 0 0 0 0 0 0
Totale 39.472